Susanna Banerjee highlighted that the NRG19 trial failed to establish non-inferiority when comparing letrozole monotherapy against standard chemotherapy followed by letrozole. Even though low-grade serous tumors express ER and PR, receptor levels do not predict response, meaning chemotherapy remains necessary.
Susanna Banerjee noted surprising durable responses during early trials of avutometinib combined with defactinib in patients whose disease had already progressed on MEK or BRAF inhibitors. The RAMP-201 trial permitted prior MEK exposure, demonstrating that simultaneous vertical and parallel pathway inhibition bypasses reactivation.
Susanna Banerjee found that blood ctDNA tests frequently missed KRAS mutations within the RAMP-201 study cohort. She emphasizes that clinicians must obtain tissue biopsies rather than relying on circulating tumor DNA, as KRAS status directs treatment outcomes for up to 30% of patients.
Susanna Banerjee shared that the single-arm Chameleon trial evaluates upfront avutometinib, defactinib, and letrozole to downsize bulky or inoperable disease. Because low-grade serous cancer responds poorly to frontline chemotherapy, targeted shrinking aims to give advanced patients the opportunity to undergo complete surgical resection.
Susanna Banerjee explained that elevated creatine phosphokinase from avutometinib and defactinib represents an asymptomatic biochemical rise rather than cardiac damage or rhabdomyolysis. Trialists initially set overly strict dose interruption guidelines before recognizing patients had no corresponding muscle symptoms.
Susanna Banerjee reported that the RAMP-201 study achieved a 17% response rate in KRAS wild-type tumors, contrasting with historic standard of care response rates of roughly 7%. This activity demonstrates that vertical RAF-MEK clamping combined with FAK inhibition extends benefit beyond the minority of patients carrying KRAS alterations.
